Nu-Med Plus Shareholders’ Equity Growth & History (NUMD)

Nu-Med Plus's shareholders’ equity was −$271,278 for fiscal 2025.

View full Nu-Med Plus company overview

Nu-Med Plus annual shareholders’ equity history

Nu-Med Plus annual shareholders’ equity

Fiscal yearPeriod endedShareholders’ equityChangeGrowth
20252025-12-31−$271,278−$56,182
20242024-12-31−$215,096−$68,345
20232023-12-31−$146,751−$83,726
20222022-12-31−$63,025$69,333
20212021-12-31−$132,358−$600,061
20202020-12-31$467,703$838,135
20192019-12-31−$370,432−$418,959
20182018-12-31$48,527−$19,715−28.89%
20172017-12-31$68,242$4.5M
20162016-12-31−$4.4M$10.8M
20152015-12-31−$15.2M−$15.2M
20142014-12-31−$53,766$70,573
20132013-12-31−$124,339−$78,255
20122012-12-31−$46,084

Nu-Med Plus shareholders’ equity trends

Over the last five fiscal years, Nu-Med Plus's shareholders’ equity decreased from $467,703 to −$271,278, a change of −$738,981. The latest reported quarter, Q2 2026, shows −$267,486.

About the metric

What shareholders’ equity means

Shareholders’ equity is the residual accounting value attributable to shareholders after liabilities are subtracted from assets. It can change through earnings, losses, dividends, share issuance, repurchases, and other comprehensive income.

Calculation and source

SEC-reported shareholders’ equity

TickerStat standardizes stockholders’ or shareholders’ equity reported in company SEC filings at each balance-sheet date. Negative equity is retained because it can be economically meaningful. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Nu-Med Plus source filings ↗

Community posts

It’s quiet here.

No posts about NUMD yet. Start the conversation.

Write the first post